Real-world clinical outcomes of patients (Pts) with metastatic colorectal cancer (mCRC) who received trifluridine-tipiracil (FTD-TPI) monotherapy or FTD-TPI plus bevacizumab (FTD-TPI plus bev) combination therapy.

被引：0
|
作者：
Nusrat, Maliha
Zhao, Ruizhi
Khan, Nadeem
Wang, Yuexi
Pierre-Victor, Dudith
Tepsick, Jon G.
Sharath, R.
Cann, Christopher G.
Salimi, Tehseen
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Taiho Oncol Inc, Princeton, NJ USA
[3] ConcertAI LLC, Cambridge, MA USA
[4] Fox Chase Canc Ctr, Philadelphia, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.4_suppl.79
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：79 / 79
页数：1
相关论文
共 45 条
  • [41] BUDGET IMPACT ANALYSIS OF TRIFLURIDINE/TIPIRACIL (FTD/TPI) AS A THIRD-LINE TREATMENT OF METASTATIC GASTRIC CANCER, INCLUDING ADENOCARCINOMA OF THE GASTROESOPHAGEAL JUNCTION, AMONG PATIENTS WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES FOR METASTATIC DISEASE IN GREECE.
    Gourzoulidis, G.
    Koulentaki, M.
    Koumarianou, A.
    Samantas, E.
    Androulakis, N.
    Xynogalos, S.
    Papakotoulas, P.
    Boukovinas, I
    Karamouzis, M.
    Souglakos, I
    Chotzagiannoglou, V
    Beletsi, A.
    Kourlaba, G.
    VALUE IN HEALTH, 2020, 23 : S431 - S432
  • [42] Evaluation of health-related quality of life (HRQoL) in patients with metastatic colorectal cancer (mCRC): A prospective, multicenter, open-label, double-arm trial of trifluridine/tipiracil (FTD/TPI) versus best supportive care (BSC).
    Karthaus, Meinolf
    Welslau, Manfred
    Riera-Knorrenschild, Jorge
    Kretzschmar, Albrecht
    Vehling-Kaiser, Ursula
    Mahlberg, Rolf
    Pelz, Henning
    Lindig, Udo
    von Weikersthal, Ludwig Fischer
    Heinemann, Volker
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [43] SOLSTICE, a phase III, randomized, open label study of trifluridine/tipiracil plus bevacizumab (bev) versus capecitabine plus bev for the 1L treatment of patients with unresectable metastatic colorectal cancer (mCRC) who are not candidates for intensive therapy
    Andre, T.
    Saunders, M. P.
    Kanehisa, A.
    Gandossi, E.
    Fougeray, R.
    Causse-Amellal, N.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2019, 30 : 250 - 250
  • [44] Effect of Tabernero's prognostic subgroups or development of neutropenia on survival outcomes of patients with refractory metastatic colorectal cancer (mCRC) treated with trifluridine/tipiracil plus bevacizumab (TASBEV) in real-world practice.
    Martinez-Lago, Nieves P.
    Alonso de Castro, Beatriz
    Reboredo Rendo, Cristina
    Calleja, Teresa
    Gomez-Randulfe Rodriguez, Martin Igor
    Silva Diaz, Sofia
    Parajo Vazquez, Iria
    Mateos Salvador, Maria
    Busto Fernandez, Fernando
    Grana Suarez, Begona
    De la Camara, Juan
    Reboredo Lopez, Margarita
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 99 - 99
  • [45] Real-world (RW) treatment patterns and clinical outcomes of patients treated with sequential regorafenib and trifluridine/tipiracil ± bevacizumab (BEV) for metastatic colorectal cancer (mCRC) in the United States (US) community oncology setting: The SEQRT2 study.
    Bekaii-Saab, Tanios S.
    Cosgrove, David
    Sruti, Ila
    Shi, Junxin
    Dai, Wei
    Patton, Gregory Alan
    Appukkuttan, Sreevalsa
    Hocum, Brian Thomas
    Katta, Arvind
    Earl, Jacob
    Babajanyan, Svetlana
    Barzi, Afsaneh
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 62 - 62
12345